Clinical Response of Tuberculosis Patients, a Prospective Cohort Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jan 3

PMID 29293580

Citations 4

Authors

Berhanu Elfu Feleke

Getu Degu Alene

Teferi Elfu Feleke

Yalmezerf Motebaynore

Fantahun Biadglegne

Affiliations

Soon will be listed here.

Abstract

Clinical response means a response to drug intake that can be detected and appreciated by a change in signs and symptoms. The objectives of this study were to assess time to clinical response, the incidence density for clinical response and determinants of clinical response of tuberculosis (TB) patients in the intensive phases of TB treatment. Prospective cohort study design was implemented. The target population for this study was all patients following the directly observed therapy. Baseline data has been collected during the start of the directly observed TB treatment strategy. We have been collected updated data after the seven days of the baseline data collection, then after every seven days updated data has been collected from each pulmonary and extra pulmonary TB patients. Kaplan Meier curve was used to estimate time to clinical response. Incidence density using person days was used to estimate incidence of clinical response. Cox proportional hazard model was used to identify the predictors of clinical responses. A total of 1608 TB patients were included with a response rate at 99.5%. The mean age of the respondents was 24.5 years [standard deviation (SD) 14.34 years]. The incidence density for clinical response was 1429/38529 person days. One fourth of the TB patients showed clinical response at day 14, 25% of at day 21 and 75% o at day 31. Predictors of clinical response for TB patients includes: age (AHR 1.007 [95% CI 1.003-1.011]), type of TB (AOR 2.3[95% CI 2.04-2.59]), Previous history of TB (AHR 0.18 [95% CI 0.11-0 .30]), Intestinal parasitic infection (AOR 0.22[95% CI 0.19-0.26]), hemoglobin (AOR 2.35 [95% CI 2.18-2.54]), weight gain (AOR 1.11 [95% CI 1.05-1.17]), Micronutrient supplementation (AOR 9.71 [95% CI 8.28-11.38]), male sex (AOR 0.87 [95% CI 0.79-0.97]).The clinical responses for extra-pulmonary TB patients were slower than pulmonary TB. Deworming and micronutrient supplementation should be considered as the additional TB treatment strategy for TB patients.

Citing Articles

Clinical heterogeneity and treatment outcomes of extrapulmonary tuberculosis in a low-incidence setting: insights from a prospective cohort study.

Klingmuller A, Feldmann M, Rohr S, Helmhold L, Junker L, Scherer M Infection. 2025; .

PMID: 40067569 DOI: 10.1007/s15010-025-02500-4.

Therapeutic drug monitoring in tuberculosis.

Sarkar M, Sarkar J Eur J Clin Pharmacol. 2024; 80(11):1659-1684.

PMID: 39240337 DOI: 10.1007/s00228-024-03749-8.

Treatment Response in Pediatric Pulmonary Tuberculosis-A Prospective Longitudinal Study.

Copelyn J, Eley B, Cox H, Workman L, Dheda K, Nicol M J Pediatric Infect Dis Soc. 2022; 11(7):329-336.

PMID: 35462407 PMC: 9302696. DOI: 10.1093/jpids/piac029.

Determinants of Weight Gain among Adult Tuberculosis Patients during Intensive Phase in Debre Markos Town Public Health Facilities, Northwest Ethiopia, 2020: Unmatched Case-Control Study.

Meselu B, Demelie B, Shedie T Tuberc Res Treat. 2022; 2022:6325633.

PMID: 35402047 PMC: 8989619. DOI: 10.1155/2022/6325633.

Intestinal parasites and HIV in Ethiopian tuberclosis patients: A systematic review and meta-analysis.

Dessie G, Negesse A, Wagnew F, Amare D, Tiruneh B, Mulugeta H Curr Ther Res Clin Exp. 2020; 93:100603.

PMID: 32963640 PMC: 7490528. DOI: 10.1016/j.curtheres.2020.100603.

References

Chiang C, Hsu C, Huang R, Lin T, Luh K . Antituberculosis drug resistance among retreatment tuberculosis patients in a referral center in Taipei. J Formos Med Assoc. 2004; 103(6):411-5. View

Tweya H, Feldacker C, Phiri S, Ben-Smith A, Fenner L, Jahn A . Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi. PLoS One. 2013; 8(2):e56248. PMC: 3574145. DOI: 10.1371/journal.pone.0056248. View

Vetter T, Jesser C . Fundamental Epidemiology Terminology and Measures: It Really Is All in the Name. Anesth Analg. 2017; 125(6):2146-2151. DOI: 10.1213/ANE.0000000000002554. View

Birlie A, Tesfaw G, Dejene T, Woldemichael K . Time to Death and Associated Factors among Tuberculosis Patients in Dangila Woreda, Northwest Ethiopia. PLoS One. 2015; 10(12):e0144244. PMC: 4687639. DOI: 10.1371/journal.pone.0144244. View

Chakravorty S, Sen M, Sivaswami Tyagi J . Diagnosis of extrapulmonary tuberculosis by smear, culture, and PCR using universal sample processing technology. J Clin Microbiol. 2005; 43(9):4357-62. PMC: 1234147. DOI: 10.1128/JCM.43.9.4357-4362.2005. View

Ciglenecki I, Glynn J, Mwinga A, Ngwira B, Zumla A, Fine P . Population differences in death rates in HIV-positive patients with tuberculosis. Int J Tuberc Lung Dis. 2007; 11(10):1121-8. View

Peloquin C . Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002; 62(15):2169-83. DOI: 10.2165/00003495-200262150-00001. View

Erickson K, Medina E, Hubbard N . Micronutrients and innate immunity. J Infect Dis. 2000; 182 Suppl 1:S5-10. DOI: 10.1086/315922. View

Brahmbhatt S, Black G, Carroll N, Beyers N, Salker F, Kidd M . Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol. 2006; 146(2):243-52. PMC: 1942062. DOI: 10.1111/j.1365-2249.2006.03211.x. View

10.

Field N, Lim M, Murray J, Dowdeswell R, Glynn J, Sonnenberg P . Timing, rates, and causes of death in a large South African tuberculosis programme. BMC Infect Dis. 2014; 14:3858. PMC: 4297465. DOI: 10.1186/s12879-014-0679-9. View

11.

Pepper D, Schomaker M, Wilkinson R, de Azevedo V, Maartens G . Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. AIDS Res Ther. 2015; 12:35. PMC: 4596495. DOI: 10.1186/s12981-015-0076-5. View

12.

Gler M, Guilatco R, Caoili J, Ershova J, Cegielski P, Johnson J . Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg. 2013; 89(5):943-9. PMC: 3820341. DOI: 10.4269/ajtmh.13-0011. View

13.

MacDonald A, Araujo M, Pearce E . Immunology of parasitic helminth infections. Infect Immun. 2002; 70(2):427-33. PMC: 127669. DOI: 10.1128/IAI.70.2.427-433.2002. View

14.

Getahun B, Ameni G, Biadgilign S, Medhin G . Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis. 2011; 11:127. PMC: 3118140. DOI: 10.1186/1471-2334-11-127. View

15.

Lam T, Ho S, Hedley A, Mak K, Peto R . Mortality and smoking in Hong Kong: case-control study of all adult deaths in 1998. BMJ. 2001; 323(7309):361. PMC: 37393. DOI: 10.1136/bmj.323.7309.361. View

16.

Oursler K, Moore R, Bishai W, Harrington S, Pope D, Chaisson R . Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis. 2002; 34(6):752-9. DOI: 10.1086/338784. View

17.

Churchyard G, Kleinschmidt I, Corbett E, Murray J, Smit J, De Cock K . Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000; 4(8):705-12. View

18.

Peloquin C . Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci. 2002; 953:157-64. DOI: 10.1111/j.1749-6632.2001.tb11374.x. View

19.

Visser M, Grewal H, Swart E, Dhansay M, Walzl G, Swanevelder S . The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr. 2010; 93(1):93-100. DOI: 10.3945/ajcn.110.001784. View

20.

Vasantha M, Gopi P, Subramani R . Survival of tuberculosis patients treated under DOTS in a rural Tuberculosis Unit (TU), south India. Indian J Tuberc. 2008; 55(2):64-9. View